Elena Milkina

Dr. Elena Milkina


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Igor ManzhuloIgor Manzhulo
Igor Manzhulo
OMOlga Manzhulo
Olga Manzhulo
ATAnna Tyrtyshnaia
Anna Tyrtyshnaia
APArina Ponomarenko
Arina Ponomarenko
SKSophia Konovalova
Sophia Konovalova
ASAnna Starinets
Anna Starinets
The present study demonstrates that synaptamide (N-docosahexaenoylethanolamine), an endogenous metabolite of docosahexaenoic acid, when administered subcutaneously (4 mg/kg/day, 14 days), exhibits analgesic activity and promotes cognitive recovery in the rat sciatic nerve chronic constriction injury (CCI) model. We analyzed the dynamics of GFAP-positive astroglia and S100β-positive astroglia activity, the expression of nerve growth factor (NGF), and two subunits of the NMDA receptor (NMDAR1 and NMDAR2A) in the hippocampi of the experimental animals. Hippocampal neurogenesis was evaluated by immunohistochemical detection of DCX. Analysis of N-acylethanolamines in plasma and in the brain was performed using the liquid chromatography-mass spectrometry technique. In vitro and in vivo experiments show that synaptamide (1) reduces cold allodynia, (2) improves working memory and locomotor activity, (3) stabilizes neurogenesis and astroglial activity, (4) enhances the expression of NGF and NMDAR1, (5) increases the concentration of Ca2+ in astrocytes, and (6) increases the production of N-acylethanolamines. The results of the present study demonstrate that synaptamide affects the activity of hippocampal astroglia, resulting in faster recovery after CCI.

15 September 2016 in Genes & Cells
Verified
Journal Article
Open access
PDF file
EMElena Milkina
Elena Milkina
PMP. V Mischenko
P. V Mischenko
SZS. V Zaytsev
S. V Zaytsev
IBI. S Bryukhovetskiy
I. S Bryukhovetskiy
IDI. V Dyuyzen
I. V Dyuyzen
ХСХотимченко Ю. С
Хотимченко Ю. С
One of the promising directions of the brain tumors treatment connected using hematopoietic stem cells (HSC). The aim of this work: to study the features of the interaction between the human stem and tumor cells of different lines. The materials for the study were CD 34+-HSCs, U87 glioblastoma, lung cancer (A549), breast cancer (MCF-7). We used cell culture methods, the robotic monitoring of cellcell interactions, confocal laser microscopy, flow cytometry. It was shown that the mobility of HSCs to glioblastoma cells was higher than to cells of lung and breast cancer. The high mobility of HSCs combined with the ability to adhere to tumor cells and to share with them the contents of the cytoplasm. A direction of transport cytoplasm was depended from the tumor cell types and is a feature of the process. We believe that the described phenomenon can be one of the mechanisms of invasive growth and also indicates a high antitumor potential of HSCs.

25 June 2026 in Pathophysiology
Verified
Journal Article
Open access
PDF file
Igor ManzhuloIgor Manzhulo
Igor Manzhulo
YKYulia Kipryushina
Yulia Kipryushina
ЕГЕкатерина Громова
Екатерина Громова
OMOlga Manzhulo
Olga Manzhulo
EMElena Milkina
Elena Milkina
DIDarya Ivashkevich
Darya Ivashkevich
Background/Objectives. Parkinson’s disease (PD) is a multifactorial neurodegenerative disorder characterized by dopaminergic neuron loss, α-synuclein pathology, neuroinflammation, and cognitive decline. Synaptamide (N-Docosahexaenoylethanolamine (DHEA)) is an endogenous lipid mediator with documented anti-inflammatory and neurogenic properties, but its effects in PD models remain unexplored. This study aimed to evaluate the neuroprotective potential of synaptamide in a subchronic MPTP-induced mouse model of PD. Methods. Male C57BL/6 mice received MPTP (30 mg/kg/day, i.p., 5 days) with or without synaptamide (10 mg/kg/day, s.c., 13 days). Behavioral tests (open field, Y-maze, elevated plus maze, novel object recognition (NOR)) were performed, followed by immunohistochemical analysis of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra, and Western blotting for α-synuclein, p-α-synuclein, TH, and IL1β in brain homogenates and serum. In vitro Neuro-2a cells were co-treated with MPP+ (100 µM) and synaptamide (0.1–10 µM) for cytotoxicity assessment (MTS assay). Results. Synaptamide (10 µM) significantly attenuated MPP+-induced cytotoxicity in Neuro-2a cells. In vivo, MPTP caused a marked loss of TH+-neurons in the substantia nigra, which was prevented by synaptamide treatment. Importantly, this subchronic MPTP model recapitulates early biochemical alterations (e.g., α-synuclein phosphorylation at Ser129) rather than mature Lewy body pathology, a limitation that should be considered when interpreting these findings. Although no motor deficits or anxiety-like behavior were observed, the NOR test revealed MPTP-induced long-term memory impairment, which was fully restored by synaptamide. Conclusions. These findings suggest that synaptamide may exert effects on pathological processes associated with PD, warranting further investigation into its potential role in combination or supportive therapy for this disease.